Subcutaneous administration of interleukin 2 and interferon-alpha-2b in advanced renal cell carcinoma: a confirmatory study
Open Access
- 1 December 1995
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 72 (6) , 1531-1535
- https://doi.org/10.1038/bjc.1995.542
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma.Journal of Clinical Oncology, 1995
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989
- SYNERGISTIC ANTITUMOR EFFECTS OF COMBINATION IMMUNOTHERAPY WITH RECOMBINANT INTERLEUKIN-2 AND A RECOMBINANT HYBRID ALPHA-INTERFERON IN THE TREATMENT OF ESTABLISHED MURINE HEPATIC METASTASES1988
- Renal cell carcinoma.Prognostic significance of morphologic parameters in 121 casesCancer, 1988
- Immunotherapy of patients with advanced cancer using interleukin-2 alone or in combination with lymphokine activated killer cells.1988
- Interferon treatment of renal cell carcinoma. Current status and future prospectsCancer, 1987
- Further experience with recombinant interferon alfa-2a with vinblastine in metastatic renal cell carcinoma: A progress reportInternational Journal of Cancer, 1987
- Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.The Journal of Immunology, 1985
- Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma.Journal of Clinical Oncology, 1985
- Reporting results of cancer treatmentCancer, 1981